11/15
Immunology
For melanoma patients, one dose of immunotherapy before surgery can lead to remission
For melanoma patients, one dose of immunotherapy before surgery can lead to remission
An Abramson Cancer Center study finds that with a single dose of a PD-1 inhibitor, immune responses can peak in just one week.
Immune profiling: A new opportunity for drug development
Immune profiling: A new opportunity for drug development
Immunologists, oncologists, and infectious disease specialists are thinking about the immune system in a new way based on its integral and ubiquitous ties to human health, amassing data on its role in gastroenterology, neurology, cardiovascular disease, and metabolic disease.
The ‘immunorevolution’ has begun
The ‘immunorevolution’ has begun
Penn Medicine experts gathered for a panel discussion about their innovative new approach to harness the body’s own immune system to fight cancer.
Abramson Cancer Center receives $10.7 million to study CAR T cells in solid tumors
Abramson Cancer Center receives $10.7 million to study CAR T cells in solid tumors
A new program project grant from the National Cancer Institute (NCI) will fund research by the Translational Center of Excellence for Lung Cancer Immunology for experimental approaches in lung cancer and mesothelioma.
Discovering a single cell that leads to relapse
Discovering a single cell that leads to relapse
Research from the Abramson Cancer Center identified a single leukemic cell, engineered for CAR T therapy, that caused a deadly recurrence of pediatric B-cell acute lymphoblastic leukemia.
CAR T cell therapy receives approval for use across European Union
CAR T cell therapy receives approval for use across European Union
The European Commission has approved a personalized cellular therapy developed at the Abramson Cancer Center, making it the first CAR T cell therapy permitted for use in the European Union in two distinct indications.
Cancer cells send out ‘drones’ to battle the immune system from afar
Cancer cells send out ‘drones’ to battle the immune system from afar
Checkpoint inhibitor therapies have made metastatic melanoma and other cancers a survivable condition, but only for some patients. Researchers uncovered a novel mechanism by which tumors suppress the immune system, raising the possibility that a straightforward blood test could predict which patients could respond to immunotherapy.
In the News
ScienceFriday.com
CAR-T cell therapies show promise for autoimmune diseases
Daniel Baker, a Ph.D. student in Carl June’s lab at the Perelman School of Medicine, discusses the results of a study on donor CAR-T cell therapy.
FULL STORY →
Live Science
‘Any protein you can imagine, it can deliver’: AI will help discover the next breakthrough in RNA, says Nobel Prize winner Dr. Drew Weissman
Drew Weissman of the Perelman School of Medicine is launching a new RNA research hub that will use artificial intelligence to help train scientists and guide their experiments.
FULL STORY →
Nature
Is bird flu spreading among people? Data gaps leave researchers in the dark
Scott Hensley of the Perelman School of Medicine says that there are fears of bird flu spreading at low levels through humans in a Missouri community.
FULL STORY →
Forbes
Carl June: 2024 will be seen as a breakthrough year for brain cancer
Carl June of the Perelman School of Medicine shares five insights on using CAR T cell therapy to combat cancer, featuring remarks from Bruce Levine.
FULL STORY →
Women’s Health
How to make yourself sneeze and find relief fast, according to doctors
John V. Bosso of the Perelman School of Medicine says that sneezing helps clear the nose of irritants, dirt, allergens, viruses, and bacteria.
FULL STORY →
The New York Times
A bird-flu pandemic in people? Here’s what it might look like
Scott Hensley of the Perelman School of Medicine says that the bird flu virus would have to change significantly to be able to bind effectively to human cells.
FULL STORY →